Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level, screening potential new therapeutics, and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]
As a the first and only market research firm to specialize in the stem cell industry, BioInformant has released the “Global Induced Pluripotent Stem Cell (iPSC) Industry Report.” Published May 2020, this 238 page global strategic report provides breaking coverage of the global iPSC market, including the effects of the COVID-19 pandemic on this rapidly evolving stem cell sector. [Read more…]
Drug discovery involves high cost and uncertain outcomes. Only a few companies can take the risk of investing enormous amounts of money into research and testing, only to see undesirable side effects emerging during the final human clinical trials. In many cases, companies are spending millions of dollars to fail during clinical testing.
Now, some new medicines are being tested for safety on specialized cells developed from human pluripotent cell lines. Cells types which are frequently being using within drug discovery applications include heart (cardiomyocytes) and liver cells (hepatocytes), which are the organs where 80% of drug failures occur. [Read more…]
Heard about iPS cells, but don’t know exactly what they are and what they can do? Read on to find out more.
In this article:
- What Are IPS Cells?
- How Are IPS Stem Cells Produced?
- What Are the Advantages of IPS Cells Over ES Cells?
- Are IPS Cells Similar to ES Cells?
- What Are the Risks of IPS Cell Use?
- What Are the Challenges in IPS Cell Research?
- Do IPS Cells Have the Potential for Medical Applications?
Adding Cell Types Supports Drug Discovery of Disease-Modifying Therapies for Neurodegenerative Diseases and Triggues U.S. $6 M Payment to Evotec
Hamburg, Germany, January 7, 2020 – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company received a US$ 6 m payment from Bristol-Myers Squibb Company (NYSE:BMY) following the decision to expand the collaboration to include additional cell lines.
Evotec and Celgene, which is now a Bristol-Myers Squibb company, initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of patients’ symptoms and there is a huge unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases.
This collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging several of Evotec’s unique technology platforms in conjunction with the human iPSC based platform, which is one of the largest and most sophisticated platforms in the industry. The iPSC partnership between Bristol-Myers Squibb and Evotec has already been expanded with additional cell lines several times. [Read more…]